Showing 91-100 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Prevalence of Endogenous Hypercortisolism in People with poorly controlled Type 1 Diabetes: Hypercortisolism In Type 1 DM (HIT-T1D) | Tulane University | Vivian Fonseca | Improving Lives | 01-October-2026 to 30-September-2029 | $2,309,103.00 |
| Targeted mRNA LNP strategies to modulate lymphocyte migration and Treg function for T1D immunotherapy | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-September-2024 to 31-August-2027 | $900,000.00 |
| A bioelectronics platform to standardize SC-islet maturation and model T1D autoimmunity | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-October-2026 to 30-September-2029 | $1,049,999.94 |
| An AI-driven bioelectronics system to accelerate SC-islet maturation | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-April-2025 to 01-March-2027 | $200,000.00 |
| Evaluating gene-modified hypo-immune PSCs for immune evasion in NHPs | Trustees of the University of Pennsylvania | Ji Lei | Cures | 01-June-2025 to 31-May-2027 | $749,999.08 |
| Engineering regulatory B cells to promote immune tolerance for islet cell replacement therapy: A novel opportunity to cure Type I diabetes | Trustees of the University of Pennsylvania | James Markmann | Cures | 01-October-2026 to 30-September-2029 | $598,995.17 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900,000.00 |
| Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: multicenter, registry-based study | Trustees of Indiana University | Viral Shah | Improving Lives | 01-September-2025 to 31-August-2028 | $1,603,777.39 |
| Design of Pump-Compatible Insulin-Glucagon Fusion Proteins | Trustees of Indiana University | Michael Weiss | Improving Lives | 01-April-2026 to 31-March-2027 | $255,749.24 |
| SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3): A POTENTIAL SURROGATE MARKER FOR TYPE-1 DIABETES PROGRESSION AND IMMUNOTHERAPY SUCCESS | Trustees of Indiana University | Jon Piganelli | Cures | 01-July-2025 to 30-June-2026 | $153,000.00 |